Skip to main navigation
logo
  • Overview
  • News & Events
    • Press Releases
    • Calendar of Events
    • Presentations
  • Financial Info
    • SEC Filings
    • Supplemental Financial Information
  • Corporate Governance
    • Documents & Charters
    • Leadership
    • Board of Directors
    • Committee Composition
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Investor Resources
    • FAQ
    • Information Requests
    • IR Contact

Lantheus Announces Presentation at the 2021 American Urological Association (AUA) Annual Meeting

  • Read more about Lantheus Announces Presentation at the 2021 American Urological Association (AUA) Annual Meeting

Lantheus Holdings to Present at Upcoming Investor Conferences

  • Read more about Lantheus Holdings to Present at Upcoming Investor Conferences

Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus’ Leadership in Prostate Cancer

  • Read more about Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus’ Leadership in Prostate Cancer

Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results

  • Read more about Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results

Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8:00 a.m. Eastern Time

  • Read more about Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8:00 a.m. Eastern Time

Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting

  • Read more about Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting

Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer

  • Read more about Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer

Lantheus Holdings Announces Presentation Featuring ¹⁸F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting

  • Read more about Lantheus Holdings Announces Presentation Featuring ¹⁸F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting

Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference

  • Read more about Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference

Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results

  • Read more about Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Current page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Site - Shareholder Services

Print Page
RSS Feeds
Email Alerts
  • Copyright © 2025 Lantheus Holdings, Inc. All rights reserved.